We present a case of a 76-year-old patient with recurrent cervical cancer who underwent first-line treatment with penpulimab combined with anlotinib. The patient was diagnosed with poorly differentiated stage III C1r cervical squamous cell carcinoma and received standard cisplatin-sensitized chemoradiotherapy, subsequently achieving a good treatment effect of complete response. Recurrence occurred nearly 14 months after treatment, with multiple metastases including in the brain and lung. Oral anlotinib was less effective, but the treatment of penpulimab combined with anlotinib showed an obvious curative effect. It has been maintained for more than 17 months, and as of April 2023 the patient is still maintaining her response. Our case suggests that penpulimab combined with anlotinib has promising efficacy in the treatment of elderly patients with recurrent cervical cancer.
Keywords: anlotinib; immunotherapy; penpulimab; recurrent cervical cancer; targeted therapy.
A 76-year-old female patient was diagnosed with cervical cancer. She received a type of treatment called chemoradiotherapy, which helped her get better. However, after 14 months of treatment, the cancer came back and spread to other parts of the body including the brain and lungs. She was given a medicine called anlotinib, which did not work very well. Then she received two medications at the same time, penpulimab and anlotinib, which worked better. Her cancer went away completely and has stayed this way for 17 months. This case shows that the combination of penpulimab and anlotinib can help treat older people with cervical cancer that comes back.